GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Short Percentage of Float

Immunic (STU:10VA) Short Percentage of Float


View and export this data going back to 2015. Start your Free Trial

What is Immunic Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Immunic's Short Percentage of Float

For the Biotechnology subindustry, Immunic's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunic's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Immunic's Short Percentage of Float falls into.


Immunic (STU:10VA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (STU:10VA) » Definitions » Short Percentage of Float
Comparable Companies
OKYO MEIP SPRB MTNB LGVN ASMB DYAI EYEN AGLE TIL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IMUX:USA 10VA:Germany
Address
1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Website
https://www.imux.com
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic (STU:10VA) Headlines

No Headlines